Drew Pardoll

Director of @BloombergKimmel Institute for Cancer Immunotherapy at Johns Hopkins. Opinions are my own.

[Drew Pardoll @dpardol1]

Watch This Insatiable Alligator Turn A Huge Python Into Its Afternoon Snack https://t.co/BkuSH5Vxqk #azanimals

[𝐉𝐨𝐡𝐧-𝐖𝐢𝐥𝐥𝐢𝐚𝐦 𝐒𝐢𝐝𝐡𝐨𝐦, 𝐌𝐃, 𝐏𝐡𝐃 @John_Will_I_Am]

Do YOU do TCR-Seq? Looking for better ways to analyze your data? If so, look no further and be sure to stop by the Convergence Minisymposium on Tuesday at 3pm to hear about DeepTCR and how you can begin using it today!! #AACR2019 #AACR19 @AACR @dpardol1

[Drew Pardoll @dpardol1]

Epic Checkpoints concert. Move over E Street Band. #SITC2018

[Bernard A Fox @BernardAFox]

“All the non-believers are immunologists since the Nobel Prize” heard at @sitcancer #SITC2018 @MDAndersonNews @HopkinsKimmel @fredhutch @ChilesResearch @bopinion @Obsidian_Tx @NobelPrize #FinishCancer @BMS_ImmunOnc_US @Merck @BloombergKimmel @Asthika @BernardAFox

[𝐉𝐨𝐡𝐧-𝐖𝐢𝐥𝐥𝐢𝐚𝐦 𝐒𝐢𝐝𝐡𝐨𝐦, 𝐌𝐃, 𝐏𝐡𝐃 @John_Will_I_Am]

Excited to release DeepTCR, a python package for uncovering structure in TCRSeq data using unsupervised and supervised deep learning methods! Will be speaking on it @ #SITC2018 this Friday!! @larmanlab @dpardol1

[Drew Pardoll @dpardol1]

Stay tuned for anti-PD-1 + PARP inhibitor combos in three cancers with only single digit response rates to anti-PD-1 single agent – breast, ovarian and prostate ca. ORR could go to >20% ORR. And NOT only for BRCA-pathway mutant cancers. Could benefit >300K additional pts/yr.

[Drew Pardoll @dpardol1]

1st clear evidence of survival benefit for kidney ca with combo of a “targeted” drug – a VEGF receptor TKI (Pfizer's axitinib)- together with a checkpoint inhibitor (Merck's Keytruda). Most impressive combo yet. More TKI+CPI combos to roll out in next yr.​
https://t.co/xDkAxWndwR

[Drew Pardoll @dpardol1]

Congrats to Jim Allison and Tasuku Honjo on Nobel for immune checkpoints...and to the wonderful clinical researchers and their courageous patients who turned science into transformative cancer therapy.

[Drew Pardoll @dpardol1]

FDA approves Libtayo - Regeneron's anti-PD1 - for advanced cutaneous squamous cancer with a near 50% response rate. 6th PD-1 pathway blocker approved and 14th cancer type with an FDA approved immunotherapy. More to come in the next year. https://t.co/IDIl3kiEN7

[Drew Pardoll @dpardol1]

Misperception in IO is the “Hyperprogression” phenomenon whereby anti-PD1 can “induce” tumors to grow faster. Many cancers reach an acceleration pt when aggressive clones take over. If that occurs after anti-PD1 started, looks like hyperprogression. Sloppy interpretation of data!

[Drew Pardoll @dpardol1]

Keytruda (Merck’s anti-PD1) granted FDA priority review for 1st rx of Merkel Cell cancer (MCC) – the 2nd most deadly skin cancer – based on >50% response rate lasting yrs. Chemo never helped w/ MCC. 47% pathologic CR rate when anti-PD1 given before surgery for operable MCC. Wow!

[Drew Pardoll @dpardol1]

I’m concerned the right-to-try-bill/law, which allows “terminally ill pts” to try drugs not FDA approved for their condition, will divert cancer pts AWAY from clinical trials better suited to their disease. Real unmet challenge is improving pts’ accessibility to the right trials.

[Drew Pardoll @dpardol1]

@BernardAFox Thanks @BernardAFox!!

[Drew Pardoll @dpardol1]

@Aiims1742 May the immune system force be with you.

[Drew Pardoll @dpardol1]

Combination #immunotherapy (anti-PD1+anti-CTLA4) showed a 56% response rate in melanoma brain metastases, which develop in more than 1/4 of pts – the scariest place for a cancer recurrence. Half the responses are complete! Could be another IO game-changer. https://t.co/ioe1nFYzLw

[Drew Pardoll @dpardol1]

#immunotherapy checkpoint inhibitor anti-PD-1 (Keytruda) just approved for first treatment of Head&Neck cancer – beats chemo. First major advance in treatment of this cancer in over 20 yrs. Many combo trials expanding on anti-PD-1 coming on line. https://t.co/pVQMukibo8

[Drew Pardoll @dpardol1]

2 more wins in lung ca. Anti-PD1(Keytruda)+chemo approved as first treatment for squamous lung ca & another anti-PD1(Opdivo) approved for small cell lung ca after 2 chemo failures – needs to be tested earlier. IO now brings hope for EVERY type of lung ca. https://t.co/pshqwfVEB0

[Drew Pardoll @dpardol1]

Interesting story emerging re possible synergy btwn anti-PD-1 therapies & drugs targeting receptor for VEGF – the major tumor angiogenesis growth factor. A # of VEGF receptor targeted drugs + anti-PD-1 show increased response rates in kidney, liver, uterine ca & mucosal melanoma.

[Drew Pardoll @dpardol1]

Great speaking with Dr. Bill Nelson on this week’s Cancer Matters podcast.

[Johns Hopkins Kimmel Cancer Center @hopkinskimmel]

Dr Bill Nelson speaks with @dpardol1, the Director of @BloombergKimmel, about the progress being made in empowering patient's own immune system to combat their cancer. https://t.co/oiIEyGpVBj

[Drew Pardoll @dpardol1]

Recent FDA approval of Yervoy+Opdivo combo for MSIhigh colon cancer offers an additional immunotherapy option. However, combo is significantly more toxic than Opdivo or Keytruda alone so remains to see if combo offers a superior risk/benefit.

[The ASCO Post @ASCOPost]

.@US_FDA Approves Nivolumab Plus Low-Dose Ipilimumab for Second-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer https://t.co/djyAyzUFx0 #crcsm #oncology